|
Daclizumab
resources
|
|
|
|
|
|
DRUG INFO
Daclizumab
Drug Name:
Daclizumab
Indication: For prevention of renal transplant rejection
Pharmacology: Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Mechanism Of Action: Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Drug Category: Immunosupressants; Immunomodulatory Agents; unclassified therapeutic agents (92:00.00)
Brand Names/Synonyms: Ig gamma-1 chain C region; humanized antiCD25; anti-IL-2; Zenapax (Hoffmann-La Roche Inc)
Dosage Forms: LIQUID
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Humanized anti-CD25 antibody
Chemical Formula: C6332H9808N1678O1989S42 >Humanized Anti-CD25 Light Chain 1 >Humanized Anti-CD25 Heavy Chain 2 >Humanized Anti-CD25 Light Chain 2
Half Life: 11-38 days
Drug Type: Approved Drug
# Accession No: BIOD00007
CAS Registry Number: 152923-56-3
|
|
|
|
|
|
Daclizumab News
(When available)
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
Yahoo! News (press release) Inc. (Synagis®); Roche (Zenapax®); and Wyeth (Mylotarg®). Further ... Inc. Zenapax is a registered trademark of Roche. Herceptin ...
PDL Grants Patent Licenses to Merck for Humanized Antibodies ... Jan 3, 2006
PR Newswire (press release), Inc. (Synagis(R)); Roche (Zenapax(R)); and Wyeth (Mylotarg(R)). Further information on PDL is available at http://www.pdl.com . ...
Fremont biotech firm eyes new HQ in Redwood City Dec 18, 2005
San Jose Business Journal, It's got an arrangement with Roche, which markets Zenapax to fight kidney transplant rejection, and R&D deals with a dozen companies including GlaxoSmithKline ...
|
|
|
